Drugs / TC-6987
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01296087 | Feb 2011 → Jan 2012 | asthma | Targacept Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01293669 | Jan 2011 → Jan 2012 | type 2 diabetes mellitus | Targacept Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TC-6987 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01296087 ↗ |
| Known as | TC-6987 HCl | “TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base).” NCT01293669 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL5314402 ↗ |
| Modality | Small molecule | — CHEMBL5314402 ↗ |
| Route | Oral | “oral administration of a 1mg/kg dose of TC-6987” NCT01293669 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL5314402 ↗ |